Delafloxacin,最近批准的阴离子氟喹诺酮，在国际抵抗监视计划中进行了测试。使用临床和实验室标准研究所（CLSI）肉汤微量稀释MIC测试方法，确定了7,914种指示的病原体引起急性细菌性皮肤和皮肤结构感染（ABSSSI）的体外敏感性。美国食品和药物管理局（FDA）敏感性测试断点和常规肉汤微量稀释和圆盘扩散方法的质量控制范围已得到确认。delafloxacinMIC50/90(敏感率%)结果如下:金黄色葡萄球菌,包括耐甲氧西林金黄色葡萄球菌（MRSA），0.008/0.25μg/ml(92.8%);鲁土葡萄球菌,0.016/0.03μg/ml(99.3%);化脓性链球菌,0.016/0.03μg/ml(100.0%);链球菌组,0.008/0.016μg/ml(100.0%)粪肠球菌,0.12/1μg/ml（66.2%）；肠杆菌科，0.12/4μg/ml(69.5%)。FDA临床断点用于评估德拉法星MIC和指示病原体的圆盘扩散方法之间的方法间测试协议。德拉氟沙星的方法间药敏试验分类协议是可以接受的，只有0.4%非常重要，金黄色葡萄球菌菌株中的假敏感错误。在所有FDA指定的物种中，选定的断点仅产生0.0％至1.7％的严重（非常主要和主要错误）方法间错误。从六个对照生物的三个多实验室（总共12个站点）研究中计算了这些标准化的德拉氟沙星敏感性测试方法的质量控制范围。总之,在对当代(2014年至2016年)ABSSSI病原体分离株的德拉氟沙星的FDAMIC断点的应用为使用德拉氟沙星治疗成人ABSSSI提供了额外的支持.DelafloxacinMIC和纸片扩散药敏试验方法已标准化用于临床应用，实现高的方法间分类一致性。
Delafloxacin, a recently approved anionic fluoroquinolone, was tested within an international resistance surveillance program. The in vitro susceptibilities of 7,914 indicated pathogens causing acute bacterial skin and skin structure infections (ABSSSI) were determined using Clinical and Laboratory Standards Institute (CLSI) broth microdilution MIC testing methods. The U.S. Food and Drug Administration (FDA) susceptibility testing breakpoints and quality control ranges for routine broth microdilution and disk diffusion methods were confirmed. The delafloxacin MIC50/90 (% susceptibility) results were as follows: Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), 0.008/0.25 μg/ml (92.8%); Staphylococcus lugdunensis, 0.016/0.03 μg/ml (99.3%); Streptococcus pyogenes, 0.016/0.03 μg/ml (100.0%); Streptococcus anginosus group, 0.008/0.016 μg/ml (100.0%); Enterococcus faecalis, 0.12/1 μg/ml (66.2%); and Enterobacteriaceae, 0.12/4 μg/ml (69.5%). The FDA clinical breakpoints were used to assess intermethod test agreement between delafloxacin MIC and disk diffusion methods for the indicated pathogens. The intermethod susceptibility test categorical agreement for delafloxacin was acceptable, with only 0.4% very major, false-susceptible errors among S. aureus strains. Across all FDA-indicated species, the selected breakpoints produced only 0.0 to 1.7% rates of serious (very major and major errors) intermethod error. Quality control ranges for these standardized delafloxacin susceptibility test methods were calculated from three multilaboratory (12 total sites) studies for six control organisms. In conclusion, the application of FDA MIC breakpoints for delafloxacin against contemporary (2014 to 2016) isolates of ABSSSI pathogens provides additional support for the use of delafloxacin in the treatment of adults with ABSSSI. Delafloxacin MIC and disk diffusion susceptibility testing methods have been standardized for clinical application, achieving high intermethod categorical agreement.
PDF(Pubmed)